Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label, Uncontrolled, Non-randomized, Maximal Use Pharmacokinetic Study to Evaluate the Systemic Exposure and Safety of KX2-391 Ointment 1% When Applied to 25 cm2 of the Face or Balding Scalp in Subjects With Actinic Keratosis

Trial Profile

A Phase 1 Open-label, Uncontrolled, Non-randomized, Maximal Use Pharmacokinetic Study to Evaluate the Systemic Exposure and Safety of KX2-391 Ointment 1% When Applied to 25 cm2 of the Face or Balding Scalp in Subjects With Actinic Keratosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs KX 01 (Primary)
  • Indications Actinic keratosis
  • Focus Pharmacokinetics
  • Sponsors Athenex
  • Most Recent Events

    • 20 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Aug 2019.
    • 20 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.
    • 20 Nov 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top